A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Iclusig comes too late to rescue Takeda
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
